On January 30, Attorney General Jeff Sessions announced a surge of Drug Enforcement Administration (DEA) agents and investigators over the coming month and a half, focused on pharmacies and prescribers who are dispensing unusual or disproportionate amounts of opioid drugs. The DEA will examine distribution and inventory data reported to the DEA by prescription drug manufacturers and distributors for “patterns” and “outliers” for further investigation.
‘Patterns’ in Opioid Crisis: DEA to Examine Prescription Drug Data
By Tony Maida on February 5, 2018
Posted In Big Data
Tags: American Health Lawyers Association, Attorney General Jeff Sessions, Centers for Disease Control, Controlled Substances Act, deputy inspector general for investigations, Drug Enforcement Administration agents and investigators, Gary Cantrell, health care fraud, Indian Health Services, July takedown, Medicaid, Medicare, Medicare Part D opioid prescriptions, Medicare Strikeforce Activities, Morphine Equivalent Dose (MED) levels, multi-agency enforcement operation, opioid dispending patterns, Opioid Fraud and Abuse Detection Unit, prescription drug manufacturers and distributors, SAMHSA, Substance Abuse and Mental Health Services Administration, Trump administration, US Department of Health and Human Services Office of Inspector General, US Department of Justice, US Food and Drug Administration, US opioid crisis
Tony Maida
Tony Maida counsels health care and life sciences clients on government investigations, regulatory compliance and compliance program development. Having served as a government official, Tony has extensive experience in health care fraud and abuse and compliance issues, including the federal and state Anti-Kickback and Stark Laws and Medicare and Medicaid coverage and payment rules. He represents clients in False Claims Act (FCA) qui tam matters, government audits, civil monetary penalty and exclusion investigations, and Centers for Medicare and Medicaid Services (CMS) suspension, and revocation actions, negotiating and implementing corporate integrity agreements, and making government self-disclosures. Read Tony Maida's full bio.
Tony Maida counsels health care and life sciences clients on government investigations, regulatory compliance and compliance program development. Having served as a government official, Tony has extensive experience in health care fraud and abuse and compliance issues, including the federal and state Anti-Kickback and Stark Laws and Medicare and Medicaid coverage and payment rules. He represents clients in False Claims Act (FCA) qui tam matters, government audits, civil monetary penalty and exclusion investigations, and Centers for Medicare and Medicaid Services (CMS) suspension, and revocation actions, negotiating and implementing corporate integrity agreements, and making government self-disclosures. Read Tony Maida's full bio.
Related Posts
- OIG Reports More Than $731 Million in Inappropriate Medicare Meaningful Use Payments
- Digital Health Year in Review: 2017 Trends and Looking Ahead to 2018
- False Claims Act Settlement with eClinicalWorks Raises Questions for Electronic Health Record Software Vendors
- Expanded Telemedicine Services Presented as Means to Address Opioid Crisis in New Legislation
- On the Digital Health Frontier: Developments Driving Industry Change in 2018